JP2022509156A5 - - Google Patents

Info

Publication number
JP2022509156A5
JP2022509156A5 JP2021528960A JP2021528960A JP2022509156A5 JP 2022509156 A5 JP2022509156 A5 JP 2022509156A5 JP 2021528960 A JP2021528960 A JP 2021528960A JP 2021528960 A JP2021528960 A JP 2021528960A JP 2022509156 A5 JP2022509156 A5 JP 2022509156A5
Authority
JP
Japan
Prior art keywords
seq
antibody
variable region
chain variable
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021528960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/121941 external-priority patent/WO2020108611A1/zh
Publication of JP2022509156A publication Critical patent/JP2022509156A/ja
Publication of JP2022509156A5 publication Critical patent/JP2022509156A5/ja
Pending legal-status Critical Current

Links

JP2021528960A 2018-11-30 2019-11-29 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用 Pending JP2022509156A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811448228.1 2018-11-30
CN201811448228 2018-11-30
PCT/CN2019/121941 WO2020108611A1 (zh) 2018-11-30 2019-11-29 抗cd40抗体、其抗原结合片段及其医药用途

Publications (2)

Publication Number Publication Date
JP2022509156A JP2022509156A (ja) 2022-01-20
JP2022509156A5 true JP2022509156A5 (cg-RX-API-DMAC7.html) 2023-02-13

Family

ID=70851924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021528960A Pending JP2022509156A (ja) 2018-11-30 2019-11-29 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用

Country Status (11)

Country Link
US (1) US20220025060A1 (cg-RX-API-DMAC7.html)
EP (1) EP3892634A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022509156A (cg-RX-API-DMAC7.html)
KR (1) KR20210099027A (cg-RX-API-DMAC7.html)
CN (1) CN112969714B (cg-RX-API-DMAC7.html)
AU (1) AU2019389354A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009835A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120793A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005823A (cg-RX-API-DMAC7.html)
TW (1) TW202039558A (cg-RX-API-DMAC7.html)
WO (1) WO2020108611A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025194A1 (zh) 2021-08-24 2023-03-02 江苏恒瑞医药股份有限公司 Fap/cd40结合分子及其医药用途
CN119462954B (zh) * 2022-02-21 2025-10-14 乐普创一生物科技(上海)有限公司 5t4/cd40双特异性抗体
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
WO2023186111A1 (zh) * 2022-04-02 2023-10-05 和铂医药(上海)有限责任公司 一种靶向cd40的抗原结合蛋白及其制备和应用
JP7881232B2 (ja) * 2022-05-31 2026-06-29 明済生物製薬(北京)有限公司 抗cd40抗体と抗pd-l1×cd40二重特異性抗体及びその使用
CN117229396A (zh) * 2022-06-06 2023-12-15 普米斯生物技术(珠海)有限公司 抗cd40抗体及其用途
CN117430704B (zh) * 2022-07-22 2026-05-15 广东安普泽生物医药股份有限公司 Cd40抗体或抗原结合片段及其应用
WO2024076969A1 (en) * 2022-10-04 2024-04-11 Memorial Sloan-Kettering Cancer Center Anti-cd40 antibodies and uses thereof
CN120282801A (zh) 2022-12-28 2025-07-08 苏州盛迪亚生物医药有限公司 一种cd40结合分子的组合物及医药用途
EP4652203A2 (en) * 2023-01-18 2025-11-26 Michael Kaleko Ph-selective antibody-based checkpoint inhibitors for conditional antibody-dependent cellular cytotoxicity
KR20250153216A (ko) 2023-02-24 2025-10-24 상하이 맙젠 바이오텍 리미티드 Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
TW202436358A (zh) 2023-03-01 2024-09-16 大陸商江蘇恆瑞醫藥股份有限公司 Fap/4-1bb/cd40結合分子及其醫藥用途
CN117924488A (zh) * 2023-12-13 2024-04-26 合肥天港免疫药物有限公司 阻断性cd40抗体及其应用
CN117756940A (zh) * 2023-12-22 2024-03-26 深圳市英特立捷生物科技有限公司 一种靶向人cd40的单克隆抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10308991A (ja) 1997-05-07 1998-11-17 Mitsubishi Electric Corp スピーカー取付構造
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
EP1707627B1 (en) * 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
RU2006141632A (ru) 2004-04-27 2008-06-10 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Антагонистические моноклональные анти-cd40-антитела и способы их применения
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
JP5027804B2 (ja) 2005-05-26 2012-09-19 シアトル ジェネティクス,インコーポレーテッド ヒト化抗cd40抗体およびその使用方法
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
EP2796467B1 (en) 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
US20120114652A1 (en) * 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
NO2699601T3 (cg-RX-API-DMAC7.html) 2011-04-21 2018-06-16
KR102037432B1 (ko) * 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
WO2015009853A1 (en) 2013-07-16 2015-01-22 University Of Louisville Research Foundation, Inc. Compositions for mucusal delivery, useful for treating papillomavirus infections
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
EP3180087B1 (en) * 2014-08-12 2019-03-13 Alligator Bioscience AB Combination therapies with anti cd40 antibodies
CA2980460A1 (en) * 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗cd40抗体およびその使用
PE20180315A1 (es) * 2015-06-29 2018-02-09 Bristol Myers Squibb Co Anticuerpos para cd40
MX2017016502A (es) * 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
SMT202100721T1 (it) * 2016-05-27 2022-01-10 Abbvie Biotherapeutics Inc Anticorpi anti-cd40 e loro usi
JP7573365B2 (ja) * 2016-08-12 2024-10-25 メルク パテント ゲーエムベーハー 癌の併用療法
KR20190133233A (ko) * 2017-03-30 2019-12-02 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항체-약물 접합체를 제조하는 방법
MX2019014375A (es) * 2017-06-01 2020-01-23 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.

Similar Documents

Publication Publication Date Title
CN110352200B (zh) 抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
RU2739617C2 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
BR112021005868A2 (pt) Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g
US11851460B2 (en) PD1 binding agents
KR20190117493A (ko) 항 pd-1 항체 및 그의 용도
RU2020127196A (ru) Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение
JP2017149720A5 (cg-RX-API-DMAC7.html)
JP2012509881A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
TW201041592A (en) Anti-TNF-α antibodies and their uses
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2015503909A5 (cg-RX-API-DMAC7.html)
JP2012532851A5 (cg-RX-API-DMAC7.html)
JP2014524902A5 (cg-RX-API-DMAC7.html)
AU2016334290B2 (en) Antibody to hepatitis B surface antigen and use thereof
JP2020521504A (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
US20250179195A1 (en) Anti-flt3 antibodies and compositions
CN116059341A (zh) 药物组合物及用途
KR20230117183A (ko) 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도
CA3256036A1 (en) Anti-PVRIG antibodies, pharmaceutical composition and associated uses